Description
Granulocyte colony-stimulating factor is the primary regulator of proliferation and differentiation, maturation, survival, and functions of neutrophils/
granulocytes to exert biological defense mechanisms via neutrophil progenitors in the bone marrow. The bone marrow colony-forming activity of maturing
granulocytes was recognized in various cell and tissue cultures. Murine G-CSF was first purified from a lungconditioned medium from mice injected with bacterial
endotoxin. The human G-CSF was purified from the conditioned media of tumor cell lines, and the cDNA was independently cloned in 1986 by two groups.
Clinical Use
Recombinant G-CSF therapies by filgrastim and lenograstim have been established in several indications. Primarily, G-CSF is administered to patients with severe
congenital or chronic neutropenia caused by a myeloid
maturation arrest in the bone marrow. G-CSF is also applicable to therapy-induced neutropenia developed in
cancer patients receiving myelosuppressive chemotherapy
and bone marrow transplant and in patients with acute
myeloid leukemia receiving induction or consolidation
chemotherapy. In addition, G-CSF induces the release of
hematopoietic stem and progenitor cells from the bone
marrow into the peripheral blood. Therefore, G-CSF is
used in transplantation therapy for the mobilization and
isolation of peripheral hematopoietic stem cells. The stem
cell mobilization by G-CSF is supported by multiple mechanisms, including proteolytic enzyme release, the modulation of adhesion molecules, and the activation of CXCR4
chemokine receptors. Recently, the nonhemopoietic role
of G-CSF has been evaluated in clinical trials including spinal cord injury by the ability of G-CSF for neuroprotective
and neuroregenerative actions.
Structure and conformation
The human G-CSF and its receptor (G-CSFR) form a 2:2
complex with a crossover interaction between the
Ig-like domains of the G-CSFR and GCSF. The predominant form of mature human G-CSF consists of 174 aa reduces, internally two disulfide bridges
(C36dC42 and C64dC74), and one O-glycan at T133. In
the splicing variant, consisting of 177 aa residues with
the insertion of V-S-E between L35 and C36, the biological
activity decreases 10-fold due to the modification of the
ligand-receptor conformation. The reason for the difference in the biological roles of the two forms has not yet
been elucidated.